MAXIGEN BIOTECH achieved profit growth outpacing revenue growth last year, with earnings per share (EPS) reaching NT$2.13. General Manager Cindy Chen stated that this year, the company will expand into new fields such as stem cells and exosomes. With regulatory easing and adjustments by the government, related products are expected to become new growth drivers for the company. In terms of market expansion, MAXIGEN will strengthen its presence in the Southern Hemisphere, particularly in emerging markets such as South America and Australia. Shipments to Australia are scheduled to begin this year. Although factory maintenance in February interrupted the company’s five-month streak of 30% annual revenue growth, MAXIGEN still aims for double-digit growth for the full year.
In February, MAXIGEN reported revenue of NT$396.7 million, representing year-on-year growth of 6.1%, but a month-on-month decline of 41.3%. Cindy Chen explained that from September last year through January this year, revenue growth consistently exceeded 30% year-on-year. The decline in February was mainly due to factory shutdowns for maintenance, which required time to resume operations, causing delays in inventory replenishment and shipments. Despite short-term revenue impacts, the company remains committed to its growth targets. Over the next three months, MAXIGEN plans to intensify market promotion and adjust its shipping schedules to sustain its goal of double-digit annual revenue growth.
Currently, MAXIGEN is collaborating with TCI GENE to advance knee joint cell therapy. Another product, Nasal Shield, a nasal dressing, is gradually being introduced to major hospitals and is scheduled for presentations at ENT-related medical conferences in March and April, aiming to expand its market applications. Three new products with completed formulations are progressing as planned and are expected to officially launch between the second half of 2026 and the first quarter of 2027.
Looking ahead to 2025, Cindy Chen highlighted two key strategic directions for this year. First, group company TCI GENE is actively engaged in stem cell and exosome research, which is anticipated to bring major breakthroughs in R&D for MAXIGEN. As government regulations continue to loosen, such products are expected to have opportunities for market entry and become new growth engines. Second, MAXIGEN plans to strengthen its footprint in the Southern Hemisphere, particularly expanding into South America, Australia, and Africa. The company will participate in Brazil's largest trade show in May, and shipments to Australia are set to begin this year.
In 2024, MAXIGEN achieved revenue of NT$680 million, an increase of approximately 9% over the same period in 2023. Net profit after tax reached NT$190 million, with EPS of NT$2.13. Profit grew by 14.68%, outpacing revenue growth, mainly due to effective control of selling expenses and sustained investment in research and development.
From a regional sales perspective, MAXIGEN saw significant growth in the European market in the fourth quarter of last year. Sales contribution increased from 5% in the previous quarter to 14%, largely benefiting from newly obtained certifications in Europe. Sales in Taiwan, the U.S., China, and other Asian markets remained stable.
Resource: 和康生今年聚焦雙主軸，營收續拚雙位數成長
